

FORM 7
MONTHLY PROGRESS REPORT – July 2021

Name of Listed Issuer: AMP Alternative Medical Products Inc. (the “Issuer” or “AMP” or “the Company”)

Trading Symbols: CSE: XCX; Frankfurt: C4TA; ISIN: CA0318961038

Number of Outstanding Listed Securities: 30,555,611 common shares

Date: August 6th, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced, and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” or “AMP” or “the Company” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

- 1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

In July, AMP imported pharmaceutical grade cannabis into Germany and marketed these products to large pharmacies and pharmaceutical distributors.

The Company's product catalogue in July included cannabis flowers and extracted products from Aphria, Bedrocan, and Little Green Pharma.

Please refer to our half-year letter to shareholders for more info, accessed at amp-eu.com/ansere-aktionaere/

2. Provide a general overview and discussion of the activities of management.

Management continued to focus on the development of the Company's sales team, sales growth, and the onboarding of additional supply sources and distribution channels.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

During the month of July 2021, the Company offered four varieties of cannabis flowers. Two flower products were sourced from Aphria (Canada) and two from Bedrocan (The Netherlands).

The Company also offered two extracted cannabis products sourced from Little Green Pharma (Australia).

Please refer to our half-year letter to shareholders for more info, accessed at amp-eu.com/ansere-aktionaere/

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

AMP is negotiating a supply agreement with a supplier to produce extracts under the AMP brand. AMP will qualify the supplier once international travel restrictions have been lifted between Germany and Australia.

AMP is in discussions with a Portuguese cultivator to supply AMP with branded cannabis flowers beginning in 2022.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable.

- 7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.**

Not applicable.

- 8. Describe the acquisition of new customers or loss of customers.**

Not applicable.

- 9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.**

Not applicable.

- 10. Report on any employee hiring, terminations, or lay-offs with details of anticipated length of lay-offs.**

Not applicable.

- 11. Report on any labour disputes and resolutions of those disputes if applicable.**

Not applicable.

- 12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

Not applicable.

- 13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

Not applicable.

14. Provide details of any securities issued and options or warrants granted.
Not applicable.

15. Provide details of any loans to or by Related Persons.

No loans were made to or by related parties or persons during this period.

16. Provide details of any changes in directors, officers, or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

In December 2020, the United Nations (UN) removed cannabis and cannabis resin from Schedule IV of the 1961 Single Convention on Narcotic Drugs, which had been listed alongside opioids such as heroin.

In December 2020, the European Union (EU) removed all uncertainty that cannabis with CBD and THC below 0.2% is not a narcotic, which may result in wellness products being sold without a prescription in Germany and Europe.

In October 2020, Bundestag, the German federal parliament, rejected a bill to legalize a “strictly controlled” adult-use recreational cannabis market.

In April 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak and any related adverse public health developments have adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: August 6th, 2021

Mr. Nicholas Furber
Name of Director or Senior Officer

/s/ Nicholas Furber
Signature

CFO & Director
Official Capacity

Issuer Details - Name of Issuer	For Month End	Date of Report YY/MM/DD
AMP Alternative Medical Products Inc. (Formerly AMP German Cannabis Group Inc.)	July 2021	21/08/06
Issuer Address		
Suite 224, West 5 th Avenue		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Vancouver, British Columbia, V5Y 1J4 Canada	(604) 683 9681	(604) 689 7533
Contact Name	Contact Position	Contact Telephone No.
Nicholas Furber	CFO & Director	(604) 689 7533
Contact Email Address	Web Site Address	
investor@amp-eu.com	http://www.amp-eu.com	